Insider Trading Activity For Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)
Alan K. Smith , EVP of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) reportedly Sold 437 shares of the company’s stock at an average price of 11.85 for a total transaction amount of $5,178.45 SEC Form
Insider Trading History For Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)
Analyst Ratings For Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)
These are 7 Buy Ratings .
The current consensus rating for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) is Buy (Score: 3.00) with a consensus target price of $28.43 , a potential (136.90% upside)
Analyst Ratings History For Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)
- On 9/11/2015 Guggenheim Upgraded rating Neutral to Buy with a price target of $38.00
- On 6/2/2016 SunTrust Banks, Inc. Initiated Coverage of rating Buy with a price target of $20.00
- On 8/9/2016 Citigroup Inc. Upgraded rating Neutral to Buy with a price target of $24.00
- On 8/9/2016 Piper Jaffray Companies Reiterated Rating Overweight with a price target of $25.00 to $31.00
- On 5/9/2017 Jefferies Group LLC Lower Price Target of rating Buy with a price target of $19.00 to $18.00
- On 6/24/2017 Ladenburg Thalmann Financial Services Set Price Target of rating Buy with a price target of $31.00
- On 6/26/2017 Cantor Fitzgerald Reiterated Rating Overweight with a price target of $35.00
Recent Trading Activity for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)
Shares of Bellicum Pharmaceuticals, Inc. closed the previous trading session at 12.00 down -0.18 -1.48% with 309,781 shares trading hands.